Beyond Air, Inc. reported fiscal 2026 results showing revenue of $7.7M, up from $3.7M a year earlier, while the company recorded a net loss attributable to Beyond Air, Inc. of $(33.2)M and diluted loss per share of $(4.01) for the year ended March 31, 2026.
Financial Highlights
- Revenue: $7.7M for year ended March 31, 2026, compared with $3.7M in FY 2025; YoY change 107%.
- Net income: Net loss attributable to Beyond Air, Inc. $(33.2)M for year ended March 31, 2026, improved from $(46.6)M in FY 2025.
- Diluted EPS: Loss per share $(4.01) for year ended March 31, 2026, improved from $(13.77) in FY 2025.
Business Highlights
- Revenue growth was driven by expanding hospital contracts and increased international sales.
- Began U.S. commercial marketing of LungFit® PH following FDA PMA in June 2022 and achieved CE mark in the EU in November 2024.
- Sales channels include hospitals and ventilator channels; company is also deploying devices for mask delivery >100ppm for severe lung infections.
- R&D spending was reduced as Gen II device development slowed; subsidiaries Beyond Cancer and NeuroNos continue preclinical work and Phase 1b planning.
- Operationally, the company upgraded its device fleet, recorded one‑time inventory provisions, and expanded device purchases to support commercialization.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.